氯胺酮治疗抑郁的代价:临床前与人体研究综述其神经毒性
本综述综合临床前模型与人体研究,评估氯胺酮的神经毒性潜力。动物研究显示重复或高剂量亚麻醉氯胺酮可致兴奋性毒性神经元损伤和持久认知缺陷,而低频中低剂量未见明显组织病理学改变。人体观察性研究提示频繁高剂量使用者存在记忆与执行功能损害,但鼻内艾司氯胺酮长期临床试验显示认知功能维持或轻度改善。
要点
- 重复或高剂量亚麻醉氯胺酮在动物中致兴奋性毒性神经元损伤和持久认知缺陷。
- 频繁高剂量(>1 g/天)氯胺酮使用者显示记忆与执行功能损害。
- 鼻内艾司氯胺酮(≤84 mg,每周或每两周)长期治疗认知功能维持或轻度改善。
核心结论
- 氯胺酮在超出临床试验所用剂量或频率时存在神经毒性风险。
- 临床医生超说明书使用显著高于临床试验剂量时需谨慎并考虑重复认知评估。
研究设计与样本
- 综述综合临床前模型数据,并整合艾司氯胺酮人体临床试验和娱乐性使用者观察性研究。
主要发现
- 动物研究:重复或高剂量亚麻醉氯胺酮导致一致的兴奋性毒性神经元损伤和持久认知缺陷,尤其围产期动物。
- 动物研究:低频相对低和中亚麻醉剂量(<1 mg/kg近似人体静脉等效)在大鼠和非人灵长类模型未产生明显组织病理学改变。
- 人体观察性研究:频繁高剂量(>1 g/天)氯胺酮使用者显示记忆和执行功能损害。
- 大型临床试验:鼻内艾司氯胺酮剂量高达84 mg,每周或每两周给药数年,与成人重性抑郁患者认知功能维持或轻度改善相关。
- 老年患者较低认知功能(注意、加工速度)显示一些潜在恶化,临床意义未知。
关键数值与推荐
- 动物研究:重复或高剂量亚麻醉氯胺酮致兴奋性毒性神经元损伤和持久认知缺陷。
- 动物研究:低频相对低和中亚麻醉剂量(<1 mg/kg近似人体静脉等效)未产生明显组织病理学改变。
- 人体观察性研究:频繁高剂量(>1 g/天)氯胺酮使用者显示记忆和执行功能损害。
- 大型临床试验:鼻内艾司氯胺酮剂量高达84 mg,每周或每两周给药数年,与认知功能维持或轻度改善相关。
- 老年患者较低认知功能(注意、加工速度)显示一些潜在恶化,临床意义未知。
临床怎么用
- 临床医生应谨慎,尤其超说明书处方氯胺酮剂量显著高于临床试验时。
- 偏离临床试验剂量时,应强烈考虑进行重复认知评估。
局限性
- 尚未直接比较艾司氯胺酮与超说明书外消旋氯胺酮在更高剂量下的效果。
- 需要强有力的纵向研究以进一步阐明氯胺酮神经毒性阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This review examines ketamine's neurotoxic potential across preclinical and clinical studies. The authors synthesized data from preclinical models, then integrated findings from human clinical trials of esketamine and observational studies in recreational users. Animal studies have found that repeated or high-dose subanesthetic ketamine administration results in consistent excitotoxic neuronal damage and lasting cognitive deficits, especially in perinatal animals. Infrequently administered relatively low and moderate subanesthetic doses (<1 mg/kg approximate human intravenous equivalent) do not yield overt histopathology in rat and nonhuman primate models. In humans, observational studies in frequent high-dose (>1 g/day) ketamine users show memory and executive function impairments. In contrast, a large clinical trial found that intranasal esketamine at doses up to 84 mg, administered weekly or every other week for several years, is associated with maintained or slightly improved cognitive function in adults with major depression. Lower cognitive function (attention, processing speed) showed some potential worsening among elderly patients; the clinical significance of this is unknown. Direct comparisons of esketamine and off-label racemic ketamine at higher doses have not been done. These studies underscore the potential for neurotoxic effects when ketamine is used at doses or frequencies beyond those utilized in clinical trials, highlighting a critical need for robust longitudinal research. Clinicians are advised to exercise caution, particularly when prescribing ketamine off-label at doses significantly higher than those used in clinical trials. When deviating from this in clinical practice, strong consideration should be given to conducting repeated cognitive assessments. Funding agencies should incentivize preclinical researchers to conduct studies that further elucidate the threshold of ketamine's neurotoxicity.
引用
- Li SW, Kumpf KT, Urrutia J, et al. Ketamine for Depression, but at What Cost? A Review of Ketamine's Neurotoxic Effects From Preclinical and Human Studies. Am J Psychiatry. 2025. PMID: 40926573. doi:10.1176/appi.ajp.20250276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。